Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7544734 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL11035549 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL674312 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL28143027 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL2882006 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL11703706 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL2825348 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL5606114 | 0.98 | DNM1 (0.43) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL7101036 | 0.98 | DNM1 (0.43) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL6303106 | 0.98 | DNM1 (0.43) | MEN1KMT2AMAPK1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| CN-119486699-A | Spherical particles of clay-based antimicrobial particles | 联合利华知识产权控股有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-116120909-B | Wettability-regulating crosslinking agent, fracturing fluid, and preparation and application methods thereof | 中国石油天然气集团有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-116037932-B | Silver-palladium alloy powder suitable for MLCC slurry preparation and preparation process thereof | 大连海外华昇电子科技有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-115739124-B | Cadmium sulfide nanosphere photocatalyst and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2024-08-20 | — | — | CN | claimed |
| CN-117844463-A | Gas phase corrosion inhibitor for shale gas well production string corrosion prevention and preparation method thereof | 中国石油天然气集团有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| CN-115233453-B | Anti-pilling anti-falling knitted fabric and post-treatment process thereof | 上海三枪（集团）有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-115722217-B | Tungsten oxide nanorod photocatalyst and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2024-01-26 | — | — | CN | claimed |
| EP-1226812-A2 | Hair mask generating heat on contact with moisture | Beiersdorf AG (DE) | 2002-07-31 | — | — | EP | claimed |
| EP-1217975-A1 | USING QUATERNARY AMMONIUM SALTS FOR TRANSDERMAL DRUG DELIVERY | Watson Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020045667-A1 | Non-toxic antimicrobial compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-18 | — | — | US | claimed |
| WO-2001017472-A1 | USING QUATERNARY AMMONIUM SALTS FOR TRANSDERMAL DRUG DELIVERY | WATSON PHARMACEUTICALS, INC. (US) | 2001-03-15 | — | — | WO | claimed |
| US-5883256-A | CLEANING FOR VIRAL AGENTS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | claimed |
| US-5591708-A | ALPHA-TERPINEOL, NONIONIC SURFACTANT AND SOLVENTS WITH WATER AND QUATERNARY AMMONIUM COMPOUND | RECKITT & COLMAN INC. (US) | 1997-01-07 | — | — | US | claimed |
| US-5062922-A | Storage stability, all ph's | ARAKAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-11-05 | — | — | US | claimed |
| EP-0132963-A1 | Quaternary ammonium germicides | A.B.M. CHEMICALS LIMITED (GB) | 1985-02-13 | — | — | EP | claimed |
| EP-0034126-B1 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS FOR SHAVING THE SKIN | Maggesi, Luigi (IT) | 1984-07-04 | — | — | EP | claimed |
| US-3992432-A | Phase transfer catalysis of heterogeneous reactions by quaternary salts | CONTINENTAL OIL COMPANY (US) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CD14, CD47, MYD88 | CHRM2 686/4885CHRM1 548/4885CHRM3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.